Publications by authors named "Sharon T Sullivan"

Claim this Profile
T
The impact of reduced dosing frequency of elranatamab on patient-reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM-3.
Nizar J Bahlis, Ajay K Nooka, Marco DiBonaventura, Sharon T Sullivan, Mohammad A Chaudhary

Hemasphere· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Michael H Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis, Sharon T Sullivan

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, H Miles Prince, Sharon T Sullivan

Nat Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nina D Wagner-Johnston, Andrè Goy, Maria A Rodriguez, W Christopher Ehmann, Paul A Hamlin, Sharon T Sullivan

Leuk Lymphoma· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Female genital tract shedding of CXCR4-tropic HIV Type 1 is associated with a majority population of CXCR4-tropic HIV Type 1 in blood and declining CD4(+) cell counts.
Richard E Haaland, Sharon T Sullivan, Tammy Evans-Strickfaden, Jeffrey L Lennox, Clyde E Hart

AIDS Res Hum Retroviruses· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women.
Colleen F Kelley, Sharon T Sullivan, Jeffrey L Lennox, Tammy Evans-Strickfaden, Clyde E Hart

AIDS· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status.
Sharon T Sullivan, Usha Mandava, Tammy Evans-Strickfaden, Jeffrey L Lennox, Tedd V Ellerbrock

J Virol· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.
Charlene S Dezzutti, V Nicole James, Artur Ramos, Sharon T Sullivan, Aladin Siddig

Antimicrob Agents Chemother· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dramatic 5'-residue effect on conformer distribution of short oligonucleotide retro models of the cisplatin-DNA cross-link: implications for the Lippard and cross-link distorted base pair steps present in cisplatin-DNA duplex adducts.
Sharon T Sullivan, Jamil S Saad, Francesco P Fanizzi, Luigi G Marzilli

J Am Chem Soc· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis